8-K current report · filed Oct 13, 2026

Harmony Biosciences Holdings, Inc. (HRMY) 8-K Current Report: October 13, 2026

Item 5.02Item 7.01Item EX-99.1HRMY overview

Short answer

Harmony Biosciences Holdings, Inc. (HRMY) filed an 8-K current report with the SEC on October 13, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). CEO Jeffrey M. Dayno retiring and leaving the board December 31, 2026, after leadership succession process.

Harmony Biosciences Holdings, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • CEO Jeffrey M. Dayno retiring and leaving the board December 31, 2026, after leadership succession process
  • Dayno remaining as non-executive advisor through 2027, supporting transition continuity
  • COO Peter Anastasiou becoming CEO January 1, 2027, adding pharmaceutical commercialization experience from Lundbeck
  • Anastasiou joining board as Class I director through 2027 annual meeting, replacing Dayno
  • No disclosed selection arrangements, related-party transactions, family ties or additional director compensation

Item 7.01 · Regulation FD Disclosure

  • October 12, 2026 press release announced Harmony Biosciences’ leadership transition
  • Leadership change is the core investor-relevant disclosure, with details in Exhibit 99.1
  • Transition may affect strategic execution, investor confidence, and operational continuity

Item EX-99.1 · Exhibit EX-99.1

  • CEO transition effective January 1, 2027: Peter Anastasiou succeeds Jeffrey Dayno, reducing execution uncertainty through internal succession
  • Dayno retires December 31, 2026 after nine years and remains a non-executive advisor throughout 2027
  • 2026 WAKIX net revenue guidance reaffirmed at $1.0 billion to $1.04 billion, signaling no immediate commercial outlook change
  • BP-205 multiple ascending dose study data remain expected in Q4 2026, preserving a key pipeline catalyst
  • Anastasiou brings commercial, business-development and CNS experience, supporting Harmony’s growth, partnering and capital-deployment priorities

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Harmony Biosciences Holdings, Inc. 8-K filings

Get the next HRMY 8-K as it lands

Follow HRMY for push alerts, or ask the research agent what this filing means.